Home/ Stocks/ CNSP

CNS Pharmaceuticals, Inc. Common Stock

CNSP XNAS

$2.71 +0.19 (+7.75%) ▲ 15-min delayed

Open

$2.44

High

$2.81

Low

$2.44

Volume

16.3K

Market Cap

$1.56M

About CNS Pharmaceuticals, Inc. Common Stock

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 4 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-3,218,481	$-5.76
Q2 2025	$0	$-2,374,961	$-6.42
Q1 2025	$0	$-4,301,320	$-1.58
FY 2024	$0	$-14,857,801	$-38.87

Earnings & Analyst Ratings

Next Earnings: Wed, May 13, 2026

Calendar →

Related Market News

No specific coverage for CNSP yet. Check out our latest market news or earnings calendar.

Get CNSP Alerts

Stay ahead with breaking news, price alerts, and expert analysis on CNS Pharmaceuticals, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.